Jonathan I. Lieber - 02 Nov 2026 Form 4 Insider Report for Rallybio Corp (RLYB)

Reporting relationship: Chief Financial Officer
Issuer ticker: RLYB
Reported as of: 02 Nov 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 03 Nov 2026, 17:51:01 UTC
Prior SEC filing: 02 Nov 2026
Source filing: View source filing
Reporting owner signature: By: /s/ Jonathan Lieber

Filing notes and source

Key filing fact

Jonathan I. Lieber filed Form 4 for Rallybio Corp (RLYB) on 03 Nov 2026.

Key facts

This page summarizes Jonathan I. Lieber's Form 4 filing for Rallybio Corp (RLYB).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 03 Nov 2026, 17:51.

Change

Previous filing in this sequence was filed on 02 Nov 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001350090 Primary reporting owner

Lieber Jonathan I

Relationship: Chief Financial Officer
Address: C/O RALLYBIO CORPORATION, PO BOX 325, EAST BERLIN
Signature: By: /s/ Jonathan Lieber
Signature date: 03 Nov 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

RLYB transaction

Common Stock

Options Exercise

Transaction value
Shares: +7,124
Change %: +19%
Price: $14.88^*
Shares after: 44,139
Date: 02 Nov 2026
Ownership: Direct

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

RLYB transaction Derivative

Option (Right to Buy)

Options Exercise

Transaction value
Shares: -7,124
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 02 Nov 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 7,124
Exercise price: $14.88
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The option is granted under the Company's 2021 Equity Incentive Plan. On October 26, 2026, the vesting of the option was accelerated in full, and the option became fully vested and exercisable as of that date.